The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health

NCT ID: NCT02931630

Last Updated: 2017-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-06-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of overweight and lifestyle related diseases such as cardiovascular disease (CVD) and type 2 diabetes (T2D) is increasing world wide. The metabolic syndrome (MeS) is a condition characterized by abdominal obesity, high blood lipids, high blood pressure and elevated blood sugar. MeS is associated with an increased risk of developing CVD and T2D. Dietary fibers and whey protein have independently shown beneficial effects on several of these risk factors in previous studies. Whey protein is furthermore seen to show positive effects on bone turnover.

The purpose of this trial is to investigate whether an increased intake of dietary fibers and whey protein (separately or combined) over a period of 12 weeks will affect the risk markers of MeS and bone turnover in abdominally obese subjects.

A total of 80 people with abdominal obesity will be included. The design is a randomized, double blinded, controlled dietary intervention trial. Subjects are assigned to one of four experimental groups. Each group are provided with test products containing either high or low whey protein and high or low dietary fibers to replace part of their regular diet. The subjects are instructed in how to incorporate the test products in their habitual diets in order to maintain weight stability.

The primary outcome is postprandial lipaemia (PPL) - an independent risk factor of developing CVD. PPL is estimated by performing a standardized high fat meal test during which postprandial level of triglycerides is measured. The authors hypothesize that a diet of high content of whey protein and high dietary fiber during 12 weeks will induce a reduction in PPL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Please refer to summary

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Obesity Metabolic Syndrome Type 2 Diabetes Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HP/HF

Whey protein powder / High fiber bread

Group Type EXPERIMENTAL

Whey protein powder

Intervention Type OTHER

60 g of whey protein powder

High fiber bread

Intervention Type OTHER

Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)

HP/LF

Whey protein powder / Low fiber bread

Group Type EXPERIMENTAL

Maltodextrin powder

Intervention Type OTHER

60 g of Maltodextrin powder

Low fiber bread

Intervention Type OTHER

Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)

LP/HF

Maltodextrin powder / High fiber bread

Group Type EXPERIMENTAL

Maltodextrin powder

Intervention Type OTHER

60 g of Maltodextrin powder

High fiber bread

Intervention Type OTHER

Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)

LP/LF

Maltodextrin powder / Low fiber bread

Group Type EXPERIMENTAL

Whey protein powder

Intervention Type OTHER

60 g of whey protein powder

Low fiber bread

Intervention Type OTHER

Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whey protein powder

60 g of whey protein powder

Intervention Type OTHER

Maltodextrin powder

60 g of Maltodextrin powder

Intervention Type OTHER

High fiber bread

Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)

Intervention Type OTHER

Low fiber bread

Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Waist circumference ≥ 80 cm (women)/94 cm (men)
* Age ≥40 years

Exclusion Criteria

* Significant cardiovascular, renal or endocrine disease
* History of diabetes
* ≥ 3 kg of weight gain or loss within the last 3 months
* Any change in medication within the last month
* Treatment with steroids
* Pregnancy, breastfeeding or planned pregnancy
* Psychiatric history
* Alcohol or drug addiction
* Dietary fiber supplement within the last month
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role collaborator

Rigshospitalet, Denmark

OTHER

Sponsor Role collaborator

University of California, Davis

OTHER

Sponsor Role collaborator

University of Copenhagen

OTHER

Sponsor Role collaborator

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Søren Gregersen

Chief physician, associate professor, ph.d.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Søren Gregersen, MD, ph.d.

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Knud Erik B. Knudsen, Professor

Role: STUDY_CHAIR

Department of Animal Science, University of Aarhus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital, Dep. of clinical nutrition research

Aarhus, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Fuglsang-Nielsen R, Rakvaag E, Vestergaard P, Hermansen K, Gregersen S, Starup-Linde J. The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity - A Post Hoc Analysis. Front Endocrinol (Lausanne). 2022 Mar 29;13:832897. doi: 10.3389/fendo.2022.832897. eCollection 2022.

Reference Type DERIVED
PMID: 35422766 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MERITS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Calcium, Protein and Gut Hormones
NCT03232034 COMPLETED NA